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Abstract 
Purpose: To investigate the relative changes in bone turnover and oxidative status markers of 
estrogen-deficient rats treated with Marantodes pumilum var. alata (MPva) leaf and root extracts. 
Methods: Thirty-six female Sprague-Dawley rats were divided into 6 groups (n = 6), namely: baseline 
(BL); placebo surgery (PS); ovariectomized control (OVXC); estrogen treatment (ERT); leaf extract 
treatment (MPv); and root extract treatment (MPr). Rats in all groups, except BL and PS, were 
ovariectomized to induce menopause. Through the oral route, ERT received 64.5 µg/kg/day estrogen 
(Premarin®); MPv received 20 mg/kg/day leaf extracts of MPva; MPr received 20 mg/kg/day root extract 
of MPva; while BL, OVXC, and PS served as untreated controls. At the end of 8 weeks treatment, blood 
and bone samples were collected for assay of bone turnover markers (osteocalcin and pyridinoline) and 
oxidative status markers (4-hydroxynonenal, superoxide dismutase, and glutathione peroxidase) using 
enzyme-linked immunosorbent assay (ELISA). 
Results: Significantly higher (p < 0.05) bone level of glutathione peroxidase was seen in MPv when 
compared with BL and OVXC. MPv also showed lower bone level of pyridinoline (p<0.05) compared to 
OVXC. Bone level of 4-hydroxynonenal in both MPv and MPr groups was significantly reduced (p < 
0.05) when compared with OVXC. 
Conclusion: MPva leaf showed more remarkable effects on bone turnover and oxidative stress 
markers of ovariectomized rats than its roots and estrogen treatment. Thus, the use of MPva leaf, as an 
alternative to estrogen for treating postmenopausal osteoporosis, would be preferred to its roots. 
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Postmenopausal osteoporosis is a systemic 
disease of the bone associated with micro-
architectural deterioration and loss of bone mass 
with a consequent reduction in bone quality and 
increase in risk of fracture [1]. With the 
increasing population of the elderly, osteoporosis 
now poses a huge economic and social burden. 
It is estimated to affect over 200 million women 
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worldwide with 1 out of every 3 above the age of 
50 reported to have experienced osteoporosis-
related fracture [2,3]. Fall in bone level of 
estrogen, a female sex hormone known to 
stimulate osteoblast differentiation and suppress 
osteoclast resorptive activity through a cascade 
of biochemical events, is believed to play a 
primary causative role in the development of 
postmenopausal osteoporosis [4]. 
 
Drug treatment of osteoporosis previously relied 
on the use of estrogen as a replacement therapy 
(ERT). Due to the debilitating nature of adverse 
reactions associated with ERT, alternative 
antiresorptive agents such as bisphosphonates 
(e.g. alendronate) are preferred [5]. These 
alternatives have also been reported to cause 
important adverse reactions, thus resulting in a 
surge in demand for safer alternative or 
complementary medicine for the management of 
postmenopausal osteoporosis [6]. 
 
For decades, Marantodes pumilum var. alata 
(MPva) had been used to manage female 
reproductive health problems in Malaysia [7]. 
Pharmacological studies have shown that it 
possesses osteoprotective properties [8]. A 
recent study has shown that aqueous leaf and 
root extracts of MPva, differentially preserved 
bone mineral density and micro-architecture of 
estrogen-deficient rats [9]. However, despite 
reports of varying nature and distribution of 
bioactive phytochemicals in the leaves and roots 
of MPva, very little is known about its mechanism 
of action, and the plant parts that might be 
responsible for its proven activity. In the current 
study, the comparative effects of the leaf and 
root extracts of MPva on bone turnover and 
oxidative stress markers in osteoporotic rat 
model were investigated in an attempt to 
evaluate the relative osteoprotective potentials of 
its leaves and roots. The animal model utilised in 
this study provided the opportunity to assay 
these markers in a characteristic estrogen 







The leaves and roots of Marantodes pumilum 
(Blume) Kuntze were collected on 04/06/2016 
from Delima Jelita Herbs, a cultivated site in 
Kedah, Malaysia. Professor Emeritus (Dr.) Abdul 
Latiff Mohamad of Department of Biological 
Sciences and Natural Resources, Universiti 
Kebangsaan Malaysia (UKM) identified the 
collected plant materials.  A voucher specimen 
was deposited at UKM herbarium (no. UKM-
HF131). The leaf and root specimens were air-
dried under shade, size-reduced with a rotary 
grinder and extracted in distilled water using 
reflux method at 60 ºC for 2 h. After extraction, 
the leaf and root extracts were freeze-dried so 
that they could be converted to dry extracts and 
stored at -20 ºC. 
 
Quantification of phenolics  
 
Aqueous leaf and root extracts of MPva were 
screened for phytochemicals using liquid 
chromatography-tandem mass spectrometry 
(LC/MS/MS) assay [10]. Seven standards, 
namely: gallic acid, quercetin, caffeic acid, 
kaempferol, ellagic acid, apigenin and myricetin 
were used. The array of LC/MS/MS used 
consists of AB Sciex 5500 QTrap liquid 
chromatography tandem mass spectrometer 
coupled to Agilent 1290 Infinity Ultra-high 
Performance Liquid Chromatography (UHPLC) 
system. On a Phenomenex Synergi Fusion C18 
column (100  2.1 mm, 5 m), the plant extracts 
as well as the standards were separated by 
gradient elution using different ratio of mixtures 
as mobile phase: (A) acetonitrile with 0.1 % 
formic acid and 5 mM ammonium formate, and 
(B) water with 0.1 % formic acid and 5 mM 
ammonium formate.  
 
The mobile phase was allowed to run over 15 
min at 250 - 400 μL/min flow rate. Quantification 
was done by monitoring the precursor-product 
ion transitions of the respective m/z of the 
standards using multiple reaction monitoring 
(MRM) scan; caffeic acid (m/z 179.000), gallic 
acid (m/z 169.011), kaempferol (m/z 284.916), 
apigenin (m/z 269.000), ellagic acid (m/z 





Healthy female Sprague-Dawley rats weighing 
200 - 250 g were involved in this study. The 
animals were obtained from the Laboratory 
Animal Unit of Universiti Kebangsaan Malaysia 
(UKM). All rats were housed in plastic cages with 
wood shavings bedding at room temperature of 
25 ± 3 °C, under natural day-night cycle and 
humidity. The cages were cleaned every 48 h. 
Before commencement of the experiment, the 
rats were acclimatized to the laboratory 
environment for 7 days. In the course of animal 
treatment, the rats were allowed free access to 
standard feed, Gold Coin® (0.97 % calcium, 0.85 
% phosphorus and 1.05 IU/g vitamin D3) and 
filtered portable water. All experimental 
procedures were conducted in accordance with 
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the provision of US Guide for the Use and Care 




Thirty-six rats were sorted into six groups of 6 
rats each (n = 6): Baseline (BL); placebo surgery 
(PS); untreated ovariectomized (OVXC); 
estrogen treatment (ERT); leaf extract treatments 
(MPv) and root extract treatments (MPr). With 
exception of the placebo surgery and BL groups, 
all rats were ovariectomized to induce a state of 
menopause. The ERT group was treated with 
64.5 μg/kg/day dose of estrogen (Premarin®), 
while MPv and MPr groups were treated with 20 
mg/kg/day dose of leaf and root extracts, 
respectively. Treatments were administered to 
rats as oral gavages (0.1 ml/100 g) for 8 weeks 
[12]. At the commencement of treatment and at 
the end of treatment, blood samples were 
collected from the tail vein of rats for assay of 
bone turnover markers (BTMs), pyridinoline 
(PYD) and osteocalcin (OC). Using a 
combination of ketamine-xylazine overdose and 
cervical dislocation, rats in the BL (at the 
commencement of treatment) and other groups 
(after treatment) were humanely sacrificed 
according to AVMA guidelines on euthanasia 
[13]. The right femora were harvested for assay 
of oxidative stress markers, 4-hydroxynonenal 
(4-HNE), superoxide dismutase (SOD) and 
glutathione peroxidase (GPx). During the 
treatment period, changes in animals’ body 
weight were also monitored with an electronic 
balance (Fisher Scientific, model no. 51100213). 
This study was approved by the Animal Ethics 






The method previously described by Khajuria 
was adopted [14]. After anesthetizing the animals 
with ketamine-xylazine mixture (80:10 mg/kg), 
the abdominal area was shaved and cleaned 
with 70% alcohol solution. Using a surgical blade 
(no. 11), a vertical incision creating 0.4 - 0.6 cm 
wide opening into the peritoneum was made. 
Through this opening, the underlying uterine 
tubes were pulled out by gentle retraction to 
expose the right and left ovaries. The ovaries 
were cut-off, and the uterine tubes were sutured 
and returned back to the peritoneum. The 
opening was then closed using suture and 
treated with Povidone iodine solution. 
Postoperatively, the animals were injected 0.1 
mg/kg buprenorphine (0.342 /mL) 
subcutaneously once daily for 3 days to control 
pain and 5 mg/kg enrofloxacin (Baytril®) 
intramuscularly every 12 hours for 7 days to 
prevent infection. 
 
Blood and bone sample collection 
 
Before and after treatment, 3 ml blood samples 
were collected from the tail vein of each rat and 
allowed to stand for 3 h in a 5 mL plain 
vacutainer tube. The collected blood samples 
were then centrifuged at 3000 rpm (Hereus 
Labofuge 400) for 10 min, and the supernatant 
was collected with Pasteur pipette and stored at -
70 oC. At the end of the treatment, the right 
femora were excised from the humanely 
euthanized rats. After removing all surrounding 
soft tissues, the dissected bone samples were 
wrapped with sterile gauze soaked in phosphate 
buffer solution and stored at -70 °C. 
 
Enzyme-linked immunosorbent assay (ELISA) 
 
Biochemical assay of BTMs was carried out on 
animal bone collected from animals before and 
after treatment while screening of bone oxidative 
status markers was carried out on right femora 
samples homogenized with Omni bead ruptor 24 
(Omni International Inc). Enzyme-linked 
immunosorbent assay (ELISA) was utilized using 
commercially prepared kits from licensed 
distributors. Rat PYD (Elabscience biotech, cat. 
no. E-EL-R0833) and rat OC/BGP (Elabscience 
biotech, cat. no. E-E-R0243) kits were used to 
assay PYD and OC, respectively. Rat 4-
hydroxynonenal (Cusabio Biotech, cat. no. 
EQ027232RA), superoxide dismutase (Cayman 
Chemical, cat. no. 706002), and glutathione 
peroxidase (Cayman Chemical 703102) kits were 
used to assay 4-HNE, SOD, and GPx, 
respectively. The ELISA protocol used to assay 
each marker was based on manufacturer’s 
specification as stipulated in the ‘user guide’. 
Depending on the wavelengths requirement, 
ELISA readers by TECAN Sunrise Instrument 
(model No. 16039400) or Thermo Fisher 
Scientific Sdn. Bhd (model no. 1510-01170) were 




The results obtained are expressed as mean ± 
SEM. Using SPSS software (version 20.0), the 
data were tested for normality of distribution 
using Kolmogorov-Smirnov test, analyzed with 
one-way analysis of variance (ANOVA) tool, and 
Tukey's post hoc test. P < 0.05 was considered 
statistically significant. 
 





Levels of phenolics  
 
The chromatograms obtained from liquid 
chromatography/mass spectroscopy (LC/MS) 
revealed different profiles of aqueous extracts of 
leaves and roots. It revealed the presence of 
5.540 μg/mL gallic acid and 0.070 μg/mL ellagic 
acid in the leaf extract. In the root extract, 2.240 
μg/mL gallic acid and 0.115 μg/mL ellagic acid 
were found. 
 
Oxidative stress markers 
 
Bone levels of 4-HNE were significantly lower (p 
< 0.05) in MPv and MPr groups as well as ERT 
and BL groups when compared with OVXC and 
PS groups. MPv and MPr groups further showed 
significantly lower levels (p < 0.05) of 4-HNE 
when compared with ERT and BL groups (Table 
1). Bone levels GPx enzyme were significantly 
higher (p < 0.05) in MPv group when compared 
with OVXC and BL groups (Table 1). However, 
no significant difference in bone levels of SOD 
was seen across all experimental groups (Table 
1). 
 
Table 1: Bone oxidative stress markers of 
ovariectomized rats treated with MPva leaf and root 
extracts 
 




BL 114.2 ± 8.0b,d 21.40 ± 7 0.19 ± 0.03 
PS 209 ± 13.8 45.36 ± 10 0.30 ± 0.05 
OVXC 132.8 ± 16.0b 20.12 ± 9 0.22 ± 0.03 
ERT 217.2 ± 11.8 66.33 ± 21 0.32 ± 0.06 
MPv 58.3 ± 10.8b,c,d 100.99 ± 28a 0.28 ± 0.06 
MPr 65.8 ± 19.8b,c,d 56.49 ± 25 0.24 ± 0.02 
Key: HNE: 4-hydroxynonenal; GPx: Glutathione 
peroxidase; SOD: Superoxide Dismutase; a’ indicates 
a significant difference compared to OVXC and BL 
groups; b significant difference compared to PS; c 
significant difference compared to ERT. Data 
presented as mean ± SEM (p < 0.05, ANOVA). 
 
Bone remodeling markers 
 
Significant reduction in bone levels of OC was 
seen in animals in the OVXC group when pre- 
and post-treatments levels were compared (p < 
0.05). But, no significant difference (p < 0.05) 
was seen in the pre and post-treatment bone 
levels of OC in both MPv and MPr groups, as 
well as the ERT and PS groups (Figure 1). 
However, post-treatment bone levels of 
pyridinoline were significantly lower (p < 0.05) in 
MPv, ERT and PS groups when compared to 
OVXC and MPr groups. 
  
Figure 1: Bone levels of osteocalcin in ovariectomized 
rats treated with MPva leaf and root extracts. Data 
presented as mean ± SEM (p < 0.05, ANOVA). Bars 
with the same alphabet indicate significant difference 
between pre- and post-treatment levels 
 
 
Figure 2: Bone levels of pyridinoline in ovariectomized 
rats treated with MPva leaf and root extracts. 
*significant difference compared to OVXC and MPr 
groups. Data presented as mean ± SEM (p < 0.05, 
ANOVA). Bars with the same alphabets indicate 
significant difference between pre- and post-treatment 
bone levels (p < 0.05, ANOVA) 
 




Weekly animal weight (g) 
0 1 2 3 4 5 6 7 8 
PS 252±3 256±2 256±2 255±3 258±4 261±5 258±5 260±6 264±5 
OVXC 265±11 270±12 281±13* 283±14* 288±15* 290±15* 290±16* 288±16* 291±17* 
ERT 263±8 266±8 264±9 264±8 267±9 266±8 273±10 273±10 273±10 
MPV 260±10 259±10 264±11 268±12 269±11 269±12 272±13 274±13 277±13 
MPr 259±17 262±16 261±17 261±16 264±17 268±16 269±16 270±17 272±18 
Data presented as mean ± SEM (p < 0.05, ANOVA). ‘*’ indicates significant difference compared to other 
treatment groups (p < 0.05, ANOVA). PS: placebo surgery group, OVXC: ovariectomized control group, ERT: 
estrogen treatment group, MPv: 20 mg/kg MPva leaf treatment group, MPr: 20 mg/kg MPva root treatment group 
 





Significantly lower animal weight (p < 0.05) was 
seen in MPv, MPr, ERT, and PS groups when 





Phytochemical investigation revealed the 
presence of differential quantities of 
phytoestrogenic constituents, gallic and ellagic 
acid in the leaves and roots of MPva. 
Phytoestrogens, a diverse group of plant-derived 
phenolic compounds with estrogenic biological 
properties, are widely self-prescribed as safe 
dietary supplement to postmenopausal hormone 
replacement therapy (HRT) in the management 
of menopause and postmenopausal 
osteoporosis. Isoflavones of soy, genistein, has 
been shown to conserve bone and prevent loss 
of BMD in ovariectomized rat model [15]. Like 
estrogens, phytoestrogens are known to act as 
female sex hormone by displacing oestradiol 
binding to antibodies raised against oestradiol. 
They are also known to possess antioxidant 
effects, a property that makes them more 
desirable in the management of osteoporosis 
[16]. 
 
Oxidative stress, a prime risk factor in the 
development of osteoporosis, has been reported 
to cause an accelerated bone loss due to 
induced osteoclast resorptive activities from the 
accumulated harmful free radicals [17]. Ligands 
generated from lipid oxidation during oxidative 
stress are also thought to interact with Wnt 
signaling pathway to cause decreased 
osteoblastogenesis and age-dependent 
decreased in bone formation [18]. As the bone 
remodels, bone-specific biochemical markers 
known as bone turnover markers (BTMs) are 
released into the bloodstream and eventually 
excreted in the urine. Bone or urine levels of 
BTMs have shown correlation with bone turnover 
activities, thus providing useful information on 
bone metabolism that complements bone density 
and morphology in the assessment of skeletal 
status, and monitoring of anti-resorptive drug 
therapy [19]. Clinicians and researchers have 
assayed BTMs and bone oxidative stress 
markers in both blood and urine samples to 
assess bone quality, predict the risk of fracture 
and monitor responses to drug treatment less 
invasively [6,20]. 
 
Assay outcome of rats’ oxidative status revealed 
a significantly higher bone level of GPx, an 
integral component of the body’s antioxidant 
system in rats in MPv group when compared with 
levels of rats in OVXC group (Table 1). Lower 
bone levels of Gpx seen in the OVXC group 
could be attributed to ovariectomy-induced 
estrogen deficiency in rats as higher level of GPx 
seen in MPv group may suggest reduced free 
radical generation and suppression of bone 
resorptive activities. Furthermore, significantly 
lower (p < 0.05) bone levels of 4-HNE were seen 
in rats in both MPv and MPr when compared to 
OVXC and PS groups. 
 
When compared with the ERT group that also 
showed lower (p < 0.05) level of 4-HNE when 
compared to OVXC group, both MPv and MPr 
groups showed significantly lower (p < 0.05) 
levels of 4-HNE (Table 1). 4-HNE, a product of 
lipid oxidation, has been reported to cause 
changes in proliferation and differentiation of 
osteoblast cells as well as the activation of 
osteoblast cells apoptosis. Bone level of 4-HNE 
has been reported to increase in murine skeleton 
with age [21]. Significantly lower levels of 4-HNE 
seen in both MPv and MPr groups revealed that 
both leaf and root extracts of MPva possess 
better protective effects against oxidative stress 
than estrogen treatment. However, in view of its 
effect on bone levels of GPx, the leaf extract of 
MPva possesses better antioxidant property than 
the root extract.  
 
BTMs assay in this study revealed a significant 
fall in bone level of OC in the ovariectomized rats 
when pre- and post-treatment bone levels were 
compared. Bone level of OC of rats in the MPv 
and MPr, as well as ERT and PS groups, was 
preserved throughout the course of treatment 
(Figure 1). OC, a 49-amino acid bone protein, is 
a sensitive and specific marker of osteoblast 
activity that is widely used to assess bone 
formation activities. It has been used as a 
surrogate marker in clinical evaluation of bone 
turnover in a variety of bone metabolic diseases 
and in describing the effects of anti-osteoporotic 
drugs. In early post-menopause, a temporary 
increase in bone levels of OC, which is usually 
followed by a gradual fall has been reported [22].   
Changes in bone levels of OC seen indicates 
that both the leaf and root extracts of MPva were 
able to preserve bone formation activities against 
estrogen deficiency to a similar extent as 
estrogen treatment and healthy control. 
However, the bone level of PYD, a well-
established marker of bone resorption, was 
significantly increased (p < 0.05) in rats in OVXC 
as well as MPr group after treatment, while rats 
in MPv groups showed no change in bone PYD 
levels throughout the treatment period.  
 
Bone PYD level seen in MPv groups was similar 
to that of PS and ERT groups. Furthermore, the 
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post-treatment levels of PYD were significantly 
lower (p < 0.05) in the MPv group when 
compared to levels of both OVXC and MPr 
groups (Figure 2). PYD is a non-reducible 
crosslink proteolytic fragment of matured 
collagen matrix and a direct indicator of bone 
resorptive activities. Assay of PYD levels in bone 
and urine has also been used as a tool for 
clinical assessment of fracture risk in a variety of 
bone metabolic conditions such as Paget’s 
disease and primary hyperparathyroidism, and to 
monitor anti-osteoporotic drug treatment [23]. 
Assay outcome of PYD shows that the leaf 
extract exerted better preservation of bone 
resorptive activities, which implies better anti-
resorptive activities than the root extract. 
 
High body mass index (BMI) has been shown to 
be strongly related to high bone mass. 
Osteoclast suppression due to the increased 
estrogen production caused by high BMI is 
believed to be responsible for the increase in 
bone mass [24]. Although epidemiological data 
have shown a correlation between BMI and bone 
mass, obesity is also known to exacerbate 
several health problems associated with 
menopause.  
 
In view of these challenges, the effect of MPva 
extracts on animal weight was monitored in this 
study. In the second week of treatment, 
significant weight gain was seen in rats in the 
OVXC group compared to the healthy control. In 
both the leaf and root extracts treatment groups, 
as well as estrogen treatment group, weight of 
rats was not significantly different (p < 0.05) from 
the OVXC group (Table 2). This implies that both 
the leaf and root extracts of MPva were able to 
suppress weight gain associated with estrogen 
loss, an outcome that informs the suitability of 




The leaf extract of MPva reduces oxidative 
stress, increases bone antioxidant enzyme and 
reduces bone-resorbing activity in 
ovariectomized rats. Its effects are superior to 
both those of the root extract and estrogen 
treatment. In view of the safety profile of MPva, 
its aqueous leaf extract has the potential to 
become an alternative medicine to estrogen in 
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